Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 535

1.

Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations.

Kardos P, Beeh KM, Sent U, Mueck T, Gräter H, Michel MC.

BMC Pharmacol Toxicol. 2018 Jul 4;19(1):40. doi: 10.1186/s40360-018-0229-y.

2.

Do review articles boost journal impact factors? A longitudinal analysis for five pharmacology journals.

Amiri M, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Jun 21. doi: 10.1007/s00210-018-1529-x. [Epub ahead of print]

PMID:
29926117
3.

Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium.

Sellers D, Chess-Williams R, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Jul;391(7):675-694. doi: 10.1007/s00210-018-1510-8. Epub 2018 May 28. Review.

PMID:
29808232
4.

Lower Urinary Tract Symptoms: What's New in Medical Treatment?

Peyronnet B, Brucker BM, Michel MC.

Eur Urol Focus. 2018 Jan;4(1):17-24. doi: 10.1016/j.euf.2018.04.005. Epub 2018 Apr 14. Review.

PMID:
29665997
5.

Causes and circumstances of death in a neonatal unit over 20 years.

Michel MC, Colaizy TT, Klein JM, Segar JL, Bell EF.

Pediatr Res. 2018 Apr;83(4):829-833. doi: 10.1038/pr.2018.1. Epub 2018 Feb 14.

PMID:
29443114
6.

A systematic review of urinary bladder hypertrophy in experimental diabetes: Part I. Streptozotocin-induced rat models.

Arioglu Inan E, Ellenbroek JH, Michel MC.

Neurourol Urodyn. 2018 Apr;37(4):1212-1219. doi: 10.1002/nau.23490. Epub 2018 Feb 2. Review.

PMID:
29392751
7.

Biased Agonism in Drug Discovery-Is It Too Soon to Choose a Path?

Michel MC, Charlton SJ.

Mol Pharmacol. 2018 Apr;93(4):259-265. doi: 10.1124/mol.117.110890. Epub 2018 Jan 11.

PMID:
29326242
8.

Muscarinic type-1 receptors contribute to IK,ACh in human atrial cardiomyocytes and are upregulated in patients with chronic atrial fibrillation.

Heijman J, Kirchner D, Kunze F, Chrétien EM, Michel-Reher MB, Voigt N, Knaut M, Michel MC, Ravens U, Dobrev D.

Int J Cardiol. 2018 Mar 15;255:61-68. doi: 10.1016/j.ijcard.2017.12.050. Epub 2017 Dec 22.

PMID:
29290419
9.

Innovation in cardiovascular disease in Europe with focus on arrhythmias: current status, opportunities, roadblocks, and the role of multiple stakeholders.

Prinzen FW, Dagres N, Bollmann A, Arnar DO, Bove S, Camm J, Casadei B, Kirchhof P, Kuck KH, Lumens J, Michel MC, Schwartz PJ, Van Vleymen B, Vardas P, Hindricks G.

Europace. 2018 May 1;20(5):733-738. doi: 10.1093/europace/eux095.

PMID:
28605436
10.

Revised editorial guidelines for manuscripts on the pharmacology of plant extracts.

Merfort I, Michel MC, Seifert R.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Aug;390(8):765-766. doi: 10.1007/s00210-017-1390-3. Epub 2017 Jun 6. No abstract available.

PMID:
28585064
11.

The β3 -adrenoceptor agonist mirabegron increases human atrial force through β1 -adrenoceptors: an indirect mechanism?

Mo W, Michel MC, Lee XW, Kaumann AJ, Molenaar P.

Br J Pharmacol. 2017 Aug;174(16):2706-2715. doi: 10.1111/bph.13897. Epub 2017 Jul 7.

PMID:
28574581
12.

Do β3-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?

Okeke K, Gravas S, Michel MC.

Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F859-F861. doi: 10.1152/ajprenal.00215.2017. Epub 2017 May 17. No abstract available.

PMID:
28515177
13.

Denominator changes may obscure results from single-well assays: β3-adrenoceptor ligand-induced changes of cell number as example.

Okeke K, Michel-Reher MB, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Jul;390(7):761-763. doi: 10.1007/s00210-017-1380-5. Epub 2017 May 4. No abstract available.

PMID:
28474169
14.

[How can innovative medicines stay affordable?]

Michel MC.

MMW Fortschr Med. 2017 Apr;159(6):65-67. doi: 10.1007/s15006-017-9487-7. Review. German. No abstract available.

PMID:
28374360
15.

Editorial on "Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study".

Michel MC.

Neurourol Urodyn. 2017 Nov;36(8):2192. doi: 10.1002/nau.23238. Epub 2017 Feb 21. No abstract available.

PMID:
28220531
16.

Re: The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.

Michel MC.

Eur Urol. 2017 May;71(5):834-835. doi: 10.1016/j.eururo.2017.01.029. Epub 2017 Jan 26. No abstract available.

PMID:
28131465
17.

Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data.

Yildirim O, Gottwald M, Schüler P, Michel MC.

Front Pharmacol. 2016 Dec 6;7:461. doi: 10.3389/fphar.2016.00461. eCollection 2016. Review.

18.

Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms.

Klimek L, Schumacher H, Schütt T, Gräter H, Mueck T, Michel MC.

Int J Clin Pract. 2017 Feb;71(2). doi: 10.1111/ijcp.12907. Epub 2016 Dec 7.

19.

Editorial Comment.

Michel MC.

J Urol. 2016 Dec;196(6):1808. doi: 10.1016/j.juro.2016.05.142. Epub 2016 Aug 24. No abstract available.

PMID:
27565771
20.

Impact of Formulation on the Pharmacokinetic Profile of Dutasteride.

Michel MC.

Clin Drug Investig. 2016 Sep;36(9):769-770. doi: 10.1007/s40261-016-0429-4. No abstract available.

PMID:
27364517
21.

β-Adrenoceptor-mediated Relaxation of Urinary Bladder Muscle in β2-Adrenoceptor Knockout Mice.

Propping S, Lorenz K, Michel MC, Wirth MP, Ravens U.

Front Pharmacol. 2016 May 9;7:118. doi: 10.3389/fphar.2016.00118. eCollection 2016.

22.

Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat.

Steubl D, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2016 Aug;389(8):815-7. doi: 10.1007/s00210-016-1260-4. Epub 2016 May 25. No abstract available.

PMID:
27220331
23.

Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.

Michel MC, Brunner HR, Foster C, Huo Y.

Pharmacol Ther. 2016 Aug;164:1-81. doi: 10.1016/j.pharmthera.2016.03.019. Epub 2016 Apr 27. Review.

25.

Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.

Michel MC, Gravas S.

Expert Opin Drug Saf. 2016 May;15(5):647-57. doi: 10.1517/14740338.2016.1160055. Epub 2016 Mar 21. Review.

PMID:
26954275
26.

Pathophysiological Factors in the Relationship between Chronological Age and Calculated Lung Age as Detected in a Screening Setting in Community-Dwelling Subjects.

Kardos P, Schütt T, Mück T, Schumacher H, Michel MC.

Front Med (Lausanne). 2016 Feb 3;3:2. doi: 10.3389/fmed.2016.00002. eCollection 2016.

27.

How β3 -adrenoceptor-selective is mirabegron?

Michel MC.

Br J Pharmacol. 2016 Feb;173(3):429-30. doi: 10.1111/bph.13379. No abstract available.

28.

β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project.

Michel MC, Korstanje C.

Pharmacol Ther. 2016 Mar;159:66-82. doi: 10.1016/j.pharmthera.2016.01.007. Epub 2016 Jan 22. Review.

PMID:
26808167
29.

Preclinical research strategies for newly approved drugs as reflected in early publication patterns.

Köster U, Nolte I, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2016 Feb;389(2):187-99. doi: 10.1007/s00210-015-1187-1. Epub 2015 Nov 26.

PMID:
26612507
30.

Longitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugs.

Köster U, Nolte I, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2016 Feb;389(2):201-9. doi: 10.1007/s00210-015-1185-3. Epub 2015 Nov 26.

PMID:
26612506
31.

Regulation of GAPDH expression by treatment with the β-adrenoceptor agonist isoprenaline--is GADPH a suitable loading control in immunoblot experiments?

Michel-Reher MB, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Oct;388(10):1119-20. doi: 10.1007/s00210-015-1166-6. Epub 2015 Aug 18. No abstract available.

PMID:
26278281
32.

Synthesis and evaluation in rats of homologous series of [(18)F]-labeled dopamine D 2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers.

Shalgunov V, van Wieringen JP, Janssen HM, Fransen PM, Dierckx RA, Michel MC, Booij J, Elsinga PH.

EJNMMI Res. 2015 Dec;5(1):119. doi: 10.1186/s13550-015-0119-x. Epub 2015 Jul 25.

33.

Cellular basis of detrusor smooth muscle contraction.

Michel MC.

BJU Int. 2016 Jan;117(1):177-8. doi: 10.1111/bju.13216. Epub 2015 Jul 18. No abstract available.

34.

A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.

Michel MC, Mayoux E, Vallon V.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Aug;388(8):801-16. doi: 10.1007/s00210-015-1134-1. Epub 2015 Jun 26. Review.

35.

Are blood vessels a target to treat lower urinary tract dysfunction?

Michel MC, Chess-Williams R, Hegde SS.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Jul;388(7):687-94. doi: 10.1007/s00210-015-1137-y. Epub 2015 May 31.

PMID:
26026700
36.

Le Programme de gestion thérapeutique des médicaments : 10 ans de collaboration entre les cinq centres hospitaliers universitaires du Québec.

Varin F, Turgeon M, Michel MC.

Can J Hosp Pharm. 2015 Mar-Apr;68(2):149-53. French. No abstract available.

37.

β3-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase.

Cernecka H, Kersten K, Maarsingh H, Elzinga CR, de Jong IJ, Korstanje C, Michel MC, Schmidt M.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Jul;388(7):749-59. doi: 10.1007/s00210-015-1128-z. Epub 2015 May 9.

38.

Expectations and satisfaction of academic investigators in nonclinical collaboration with the pharmaceutical industry.

Amiri M, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Jun;388(6):613-22. doi: 10.1007/s00210-015-1106-5. Epub 2015 Feb 28.

PMID:
25720948
39.

Therapeutic targets for overactive bladder other than smooth muscle.

Michel MC, Igawa Y.

Expert Opin Ther Targets. 2015 May;19(5):687-705. doi: 10.1517/14728222.2015.1009447. Epub 2015 Feb 23. Review.

PMID:
25704500
40.

How much potential for transient receptor potential channels in the bladder?

Michel MC.

BJU Int. 2015 Mar;115(3):350-1. doi: 10.1111/bju.12909. No abstract available.

41.

Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms.

Michel MC, Seifert R.

Am J Physiol Cell Physiol. 2015 Apr 1;308(7):C505-20. doi: 10.1152/ajpcell.00389.2014. Epub 2015 Jan 28. Review.

42.

Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D2/3 Receptors.

van Wieringen JP, de Bruin K, Janssen HM, Fransen PM, Janssen AG, van Doremalen PA, Michel MC, Elsinga PH, Booij J.

Int J Mol Imaging. 2014;2014:507012. doi: 10.1155/2014/507012. Epub 2014 Dec 25.

43.

Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET.

Shalgunov V, van Wieringen JP, Janssen HM, Fransen PM, Dierckx RA, Michel MC, Booij J, Elsinga PH.

J Nucl Med. 2015 Jan;56(1):133-9. doi: 10.2967/jnumed.114.145466. Epub 2014 Dec 4.

44.

Dynamic bias and its implications for GPCR drug discovery.

Michel MC, Seifert R, Bond RA.

Nat Rev Drug Discov. 2014 Nov;13(11):869. doi: 10.1038/nrd3954-c3. Epub 2014 Oct 17. No abstract available.

PMID:
25323926
45.

Therapeutic modulation of urinary bladder function: multiple targets at multiple levels.

Michel MC.

Annu Rev Pharmacol Toxicol. 2015;55:269-87. doi: 10.1146/annurev-pharmtox-010814-124536. Epub 2014 Sep 10. Review.

PMID:
25251997
46.

How significant are your data? The need for a culture shift.

Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2014 Nov;387(11):1015-6. doi: 10.1007/s00210-014-1044-7. Epub 2014 Aug 30. No abstract available.

PMID:
25172524
47.

Rat β₃-adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues.

Cernecka H, Pradidarcheep W, Lamers WH, Schmidt M, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2014 Nov;387(11):1117-27. doi: 10.1007/s00210-014-1039-4. Epub 2014 Aug 30. Erratum in: Naunyn Schmiedebergs Arch Pharmacol. 2014 Nov;387(11):1129.

PMID:
25172522
48.

Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms.

Oelke M, Gericke A, Michel MC.

Expert Opin Drug Saf. 2014 Sep;13(9):1187-97. doi: 10.1517/14740338.2014.936376. Epub 2014 Jul 29. Review.

PMID:
25073735
49.

Hope for disease-modifying treatment of systemic sclerosis/scleroderma.

Michel MC.

J Pharmacol Exp Ther. 2014 Sep;350(3):480-2. doi: 10.1124/jpet.114.213520comm. No abstract available.

50.

The odd sibling: features of β3-adrenoceptor pharmacology.

Cernecka H, Sand C, Michel MC.

Mol Pharmacol. 2014 Nov;86(5):479-84. doi: 10.1124/mol.114.092817. Epub 2014 Jun 2. Review.

Supplemental Content

Loading ...
Support Center